WVE News and Press, Wave Life Sciences Ltd. From 05/02/23

2023-05-02 13:14:01 ET Wave Life Sciences ( NASDAQ: WVE ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is -$0.04 (+93.5% Y/Y) and the consensus Revenue Estimate is $38.6M (+2105.7% Y/Y). Over the las...

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Wednesd...

Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA formats RNAi is one of multiple Wave modalities being advanced in strategic research c...

CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive...

2023-03-22 11:55:23 ET Wave Life Sciences Ltd (WVE) Q4 2022 Earnings Conference Call March 22, 2023 08:30 AM ET Company Participants Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Fina...

2023-03-22 10:02:09 ET Gainers: 89bio ( ETNB ) +38% . SCYNEXIS ( SCYX ) +21% . Athersys ( ATHX ) +20% .  Sol-Gel Technologies ( SLGL ) +19% . LifeMD ( LFMD ) +11% . Losers: NuCana ( NCNA ) -10% . Nutex Hea...

2023-03-22 09:21:50 ET The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2022 Q4 earnings call. For further details see: Wave Life Sciences Ltd. 2022 Q4 - Results - Earnings Call Presentation

2023-03-22 07:40:49 ET Wave Life Sciences press release ( NASDAQ: WVE ): Q4 GAAP EPS of -$0.47 misses by $0.06 . Revenue of $1.24M (-29.5% Y/Y) misses by $1.16M . As of December 31, 2022, Wave had $88.5 million in cash and cash equivalents, as co...

Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended leadership in RNA editing and advanced WVE-006 for AATD – first-in-class RNA editing candidate tra...

2023-03-21 11:46:42 ET Wave Life Sciences ( NASDAQ: WVE ) is scheduled to announce Q4 earnings results on Wednesday, March 22nd, before market open. The consensus EPS Estimate is -$0.41 (+32.8% Y/Y) and the consensus Revenue Estimate is $2.4M (+36.4% Y/Y). Over the las...